STAMFORD, Conn. --(BUSINESS WIRE)--Jan. 17, 2025-- GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that, effective as of January 14, 2025 , the compensation committee of GeneDx’s board of directors granted a total of
Expects to exceed guidance with full year 2024 revenues 1 of at least $299 million Expects fourth quarter 2024 revenues 1 of at least $92 million Expects to exceed guidance with full year 2024 adjusted gross margin 1 of at least 64% Expects fourth quarter 2024 adjusted gross margin 1 of at least
STAMFORD, Conn. --(BUSINESS WIRE)--Jan. 9, 2025-- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced a new way to provide genetic counseling and test-ordering services for patients and families seeking access to genetic testing.
Contributed nearly one quarter of all submissions to GeneMatcher and collaborated on more than 85 peer reviewed publications in 2024 STAMFORD, Conn. --(BUSINESS WIRE)--Jan. 8, 2025-- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, continues its
Experienced Diagnostics Executive with a Proven Record of Driving Business Growth to Lead Product & Technology, Operations, Medical Affairs, Innovation and More New Executive Leadership Positions Company for Growth and Scale STAMFORD, Conn. --(BUSINESS WIRE)--Jan.